PI, Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost
Pavlides, Gregory, SHIELD II(HeartMate PHP) Supporting Patients Undergoing High-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device, 19739, Thoratec Corporation, 10/05/16-08/31/18, $61,617, $15,240, $76,857
Windle, John Robert, Optimizing the Electronic Health Record for Cardiac Care, 16308, DHHS/AHRQ, 09/01/16-08/31/17, $357,839, $123,286, $481,125
Desouza, Cyrus Victor, GRADE [Glycemic Reduction Approaches for Diabetes: A Comparative Effectiveness Study], 15785, George Washington University, 08/01/16-07/31/17, $480,280, $213,303, $693,583
Desouza, Cyrus Victor, PIONEER 5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment, 20200, Novo Nordisk Pharmaceuticals, Inc., 09/12/16-07/31/18, $51,729, $13,190, $64,919
Desouza, Cyrus Victor, A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events, 20505, Theracos Sub, LLC, 12/15/16-12/14/20, $495,548, $128,582, $624,130
Casey, Carol A, Nebraska Center for Integrated Biomolecular Communication (CIBC), 20437, University of Nebraska – Lincoln, 08/15/16-06/30/17, $7,483, $3,779, $11,262
Olivera Martinez, Marco A, A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1 (CONFIRM STUDY), 19935, Malllinckrodt Hospital Products, Inc., 10/25/16-10/24/17, $119,540, $30,430, $149,970
Rasineni, Karuna, Pancreas-Adipose-Liver Axis: Role of Ghrelin and Insulin in Alcoholic Fatty Liver, 19221, DHHS/NIH/NIAAA, 05/05/16-04/30/17, $11,000, $880, $11,880
Bonasera, Stephen John, Live Well: A Mobile Intervention for Bipolar Disorder, 20614, Northwestern University-Chicago, 07/15/16-06/30/17, $4,515, $2,280, $6,795
Bonasera, Stephen John, The UCSF and UNMC Dementia Care Ecosystem: Using Innovative Technologies to Personalize and Deliver Coordinated Dementia Care, 17581, University of California – San Francisco, 09/01/16-08/31/17, $968,826, $175,693, $1,144,519
Bares, Sara, Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants, 20498, Brigham & Women’s Hospital, 03/01/16-02/28/17, $8,700, $4,394, $13,094
Florescu, Diana Florentina, A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir TreatmentCompared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections…, 20062, Shire ViroPharma, Inc., 12/27/16-12/26/19, $155,342, $40,129, $195,471
Rupp, Mark E, An Open-label, Prospective, Observational Study of the Wear Time of an Investigational Antimicrobial Dressing containing CHG, 20174, 3M Company, 11/09/16-11/08/17, $80,094, $20,044, $100,138
Swindells, Susan, National AIDS Education and Training Center Grants, 530, University of Illinois – Chicago, 07/01/16-06/30/17, $147,174, $11,774, $158,948
AIDS Drug Assistance Program [ADAP] Ryan White Title II Program (Part B), 1285, NE DHHS, 10/15/16-09/29/17, $2,462,600, $0, $2,462,600
Holstein, Sarah A, Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma, 20623, DHHS/NIH/NCI, 08/12/16-12/31/17, $79,104, $38,232, $117,336
Lunning, Matthew A, Long-Term Follow-up Protocol for Subjects Treated with JCAR015, 20166, Juno Therapeutics, Inc., 08/23/16-08/22/21, $148,821, $37,913, $186,734
A Single-center Phase IIa Study Evaluating the Safety and Tolerability of TGR-1202 and Ibrutinib in Patients with Relapse/Refractory Diffuse Large B-cell Lymphoma, 19499, Janssen Scientific Affairs, LLC, 10/07/16-12/31/18, $425,539, $105,895, $531,434
Bailey, Kristina Lynn, Mucociliary clearance in aging, 19544, DHHS/NIH/NIA, 09/30/16-04/30/17, $206,812, $89,290, $296,102
Dickinson, John David, Autophagy regulates airway epithelial cell mucin secretion, 19322, DHHS/NIH/NHLBI, 09/15/16-08/31/17, $148,000, $11,840, $159,840
Gries, Tara Marie, Role of agricultural dust exposures on lung-resident mesenchymal stem/stromal cell function, 20422, Colorado State University, 11/01/16-08/15/17, $18,519, $1,481, $20,000
Murphy, P. James James, A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, andLumacaftor and Ivacaftor Combination Therapy in Subjects with…, 17460, Vertex Pharmaceuticals Incorporated, 01/22/14-01/21/15, $0, $6,358, $6,358
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects with…, 17460, Vertex Pharmaceuticals Incorporated, 01/22/14-01/21/15, $30,099, $8,476, $38,575
Poole, Jill Adair, Role of Pattern Recognition Receptors in Organic Dust-induced Airway Inflammation, 14123, DHHS/NIH/NIEHS, 01/01/17-12/31/17, $287,070, $144,970, $432,040
Rennard, Stephen Israel, Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC), 19461, University of Pittsburgh, 08/01/16-07/31/17, $6,839, $3,454, $10,293
Wichman, Tammy O, Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program [PAH-QuERI Registry] – Dr. Tammy Wichman, 20015, Actelion Pharmaceuticals US, Inc., 10/04/16-10/03/17, $2,690, $569, $3,259
Cannella, Amy Christine, FY 2017 Amgen Fellowship Training Award, 19998, Rheumatology Research Foundation, 07/01/17-06/30/18, $50,000, $0, $50,000
Mikuls, Ted Richard, CORT Project 4: A Novel Centralized ‘Virtual’ Gout Clinic for Chronic Gout Management, 14644, University of Alabama – Birmingham, 09/01/16-08/31/17, $106,277, $51,544, $157,821
Mikuls, Ted Richard, Novel Methods for Ascertainment of Gout Flares – A Pilot Study (GoutPRO), 20254, University of Alabama – Birmingham, 12/06/16-05/31/17, $56,300, $14,378, $70,678